Ruxolitinib in GvHD (RIG) study: a multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versus-host disease (aGvHD) (NCT02396628)
Journal article published in 2018 by
Nikolas von Bubnoff 
,
Gabriele Ihorst,
Olga Grishina,
Nadine Röthling,
Hartmut Bertz,
Justus Duyster,
Jürgen Finke,
Robert Zeiser
,
Gabriele Ihorst,
Olga Grishina,
Nadine Röthling,
Hartmut Bertz,
Justus Duyster,
Jürgen Finke,
Robert Zeiser
This paper is made freely available by the publisher.
Full text: Download
Data provided by 